Estrogen-Based Gender-Affirming Hormone Therapy and Subclinical Cardiovascular Disease in Transgender Women with HIV
LGBT Health · 2023
DOI: 10.1089/lgbt.2023.0010 ↗Kurz gefasst
Fachartikel in der Zeitschrift LGBT Health, 2023. Verfasst von Claudia A Martinez und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA. Hauptthemen laut MEDLINE: Cardiovascular Diseases, HIV Infections, Transgender Persons. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIAID NIH HHS, NIDA NIH HHS.
Abstract (Originalsprache)
Purpose
Transgender women (TW) are disproportionately affected by HIV infection and cardiovascular disease (CVD). This study evaluated whether estrogen-based gender-affirming hormone therapy (GAHT) in TW with HIV (TWH-GAHT) is associated with indices of subclinical CVD.
Methods
Of the 40 HIV-seropositive persons enrolled, 20–60 years of age, on antiretroviral treatment with undetectable viral load, assessments were performed on 15 TWH; of these persons, 11 were GAHT treated. These TWH-GAHT were matched with HIV+ cisgender men and women based on age, ethnicity/race, body mass index, and antihypertensive medication use. Sex hormones, and cardiometabolic (waist circumference, blood pressure, insulin resistance, lipid profile, and C-reactive protein), vascular (flow-mediated dilation [FMD] and arterial stiffness), and proinflammatory measures were obtained.
Results
TWH-GAHT displayed elevated estradiol and suppressed testosterone levels relative to normative ranges. Analyses indicated the TWH-GAHT displayed lower low-density lipoprotein compared with cisgender groups ( p < 0.05). Although no difference was seen on FMD, the central augmentation index of aortic stiffness was higher in cisgender HIV+ women than cisgender HIV+ men ( p < 0.05). No other group difference on subclinical CVD markers was observed. For TWH, partial correlations indicated associations of certain sex hormones with selected cardiometabolic outcomes and the inflammatory cytokine, interleukin-8.
Conclusion
When well matched to HIV+ cisgender men and women, subclinical CVD pathophysiology did not appear elevated in TWH-GAHT, although tendencies emerged suggesting that some subclinical CVD indices may be higher, but others lower than cisgender groups. Longitudinal studies of TWH are needed to more precisely evaluate the moderating effect of GAHT on cardiometabolic pathophysiology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiovascular Medicine, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.
- Division of Cardiology, Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
- Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.
- Behavioral Medicine Research Center and Department of Psychology, University of Miami, Miami/Coral Gables, Florida, USA.
- Division of Cardiology, Department of Medicine, University of Washington, Seattle, Washington, USA.
- Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida, USA.
ORCID-Profile: Claudia A Martinez, Nicholas Fonseca Nogueira, Joseph P De Santis
Förderung
- NHLBI NIH HHS
- NIAID NIH HHS
- NIDA NIH HHS
Zitieren
APA
Martinez, C. A., Rikhi, R., Fonseca Nogueira, N., Pester, M. S., Salazar, A. S., Ashinne, B., Aguilar, N., Melara, A., Porras, V., Parker, M., Mendez, A., Cyrus, E., De Santis, J. P., Jones, D. L., Brown, T. T., Hurwitz, B. E., & Alcaide, M. L. (2023). Estrogen-Based Gender-Affirming Hormone Therapy and Subclinical Cardiovascular Disease in Transgender Women with HIV. LGBT Health. https://doi.org/10.1089/lgbt.2023.0010
Vancouver
Martinez CA, Rikhi R, Fonseca Nogueira N, Pester MS, Salazar AS, Ashinne B, et al. Estrogen-Based Gender-Affirming Hormone Therapy and Subclinical Cardiovascular Disease in Transgender Women with HIV. LGBT Health. 2023. doi:10.1089/lgbt.2023.0010
BibTeX
@article{Martinez2023,
author = {Martinez, Claudia A and Rikhi, Rishi and Fonseca Nogueira, Nicholas and Pester, Mollie S and Salazar, Ana S and Ashinne, Beteal and Aguilar, Natalie and Melara, Abraham and Porras, Valeria and Parker, Meela and Mendez, Armando and Cyrus, Elena and De Santis, Joseph P and Jones, Deborah L and Brown, Todd T and Hurwitz, Barry E and Alcaide, Maria L},
title = {Estrogen-Based Gender-Affirming Hormone Therapy and Subclinical Cardiovascular Disease in Transgender Women with HIV},
journal = {LGBT Health},
year = {2023},
doi = {10.1089/lgbt.2023.0010}
}
EUVIMED